Antibody response in goats vaccinated with liposome-adjuvanted Clostridium perfringens type D epsilon toxoid

Francisco A Uzal, J. P. Wong, W. R. Kelly, J. Priest

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

A trial was performed using 20 goats to evaluate the antibody responses to a liposome-adjuvanted Clostridium perfringens epsilon toxoid vaccine (LIPV). The antibody response was compared with those produced by epsilon toxoid vaccines prepared using aluminium hydroxide (ALV) and incomplete Freud's adjuvant (FAV). The animals were allocated to four groups at the beginning of the trial. The animals in group 1 were vaccinated with ALV, while the animals in group 2 received FAV and those in groups 3 and 4 were vaccinated with LIPV. The animals in groups 1 to 3 received three doses of the corresponding vaccine at intervals of three weeks, while those in group 4 received only 1 dose of vaccine at the beginning of the trial. A blood sample was obtained from all the goats at the beginning of the trial and then weekly for 8 weeks. The samples were analysed for epsilon toxoid antibodies by an indirect ELISA technique. No major clinical abnormalities were observed in the animals after vaccination, with the exception of those that received the FAV, which experienced transient lameness. The highest antibody response was observed in the animals vaccinated with FAV, but they presented moderate to severe inflammatory tissue reactions at the injection site. Moderately high antibody responses were obtained with the ALV, with which only minor local reactions were observed. No significant antibody responses were obtained with the LIPV, nor were local reactions observed.

Original languageEnglish (US)
Pages (from-to)143-150
Number of pages8
JournalVeterinary Research Communications
Volume23
Issue number3
DOIs
StatePublished - 1999
Externally publishedYes

Fingerprint

Clostridium perfringens D
Toxoids
Clostridium perfringens
toxoids
Goats
Liposomes
Antibody Formation
goats
adjuvants
antibodies
Vaccines
vaccines
animals
Aluminum Hydroxide
aluminum hydroxide
injection site
dosage
lameness
Vaccination
Enzyme-Linked Immunosorbent Assay

Keywords

  • Adjuvant
  • Antibody
  • Clostridium perfringens
  • Enterotoxaemia
  • Goats
  • Immunity
  • Liposomes
  • Vaccines

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Antibody response in goats vaccinated with liposome-adjuvanted Clostridium perfringens type D epsilon toxoid. / Uzal, Francisco A; Wong, J. P.; Kelly, W. R.; Priest, J.

In: Veterinary Research Communications, Vol. 23, No. 3, 1999, p. 143-150.

Research output: Contribution to journalArticle

@article{957da68e2f124fcfaaa157c1d70c9850,
title = "Antibody response in goats vaccinated with liposome-adjuvanted Clostridium perfringens type D epsilon toxoid",
abstract = "A trial was performed using 20 goats to evaluate the antibody responses to a liposome-adjuvanted Clostridium perfringens epsilon toxoid vaccine (LIPV). The antibody response was compared with those produced by epsilon toxoid vaccines prepared using aluminium hydroxide (ALV) and incomplete Freud's adjuvant (FAV). The animals were allocated to four groups at the beginning of the trial. The animals in group 1 were vaccinated with ALV, while the animals in group 2 received FAV and those in groups 3 and 4 were vaccinated with LIPV. The animals in groups 1 to 3 received three doses of the corresponding vaccine at intervals of three weeks, while those in group 4 received only 1 dose of vaccine at the beginning of the trial. A blood sample was obtained from all the goats at the beginning of the trial and then weekly for 8 weeks. The samples were analysed for epsilon toxoid antibodies by an indirect ELISA technique. No major clinical abnormalities were observed in the animals after vaccination, with the exception of those that received the FAV, which experienced transient lameness. The highest antibody response was observed in the animals vaccinated with FAV, but they presented moderate to severe inflammatory tissue reactions at the injection site. Moderately high antibody responses were obtained with the ALV, with which only minor local reactions were observed. No significant antibody responses were obtained with the LIPV, nor were local reactions observed.",
keywords = "Adjuvant, Antibody, Clostridium perfringens, Enterotoxaemia, Goats, Immunity, Liposomes, Vaccines",
author = "Uzal, {Francisco A} and Wong, {J. P.} and Kelly, {W. R.} and J. Priest",
year = "1999",
doi = "10.1023/A:1006206216220",
language = "English (US)",
volume = "23",
pages = "143--150",
journal = "Veterinary Research Communications",
issn = "0165-7380",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - Antibody response in goats vaccinated with liposome-adjuvanted Clostridium perfringens type D epsilon toxoid

AU - Uzal, Francisco A

AU - Wong, J. P.

AU - Kelly, W. R.

AU - Priest, J.

PY - 1999

Y1 - 1999

N2 - A trial was performed using 20 goats to evaluate the antibody responses to a liposome-adjuvanted Clostridium perfringens epsilon toxoid vaccine (LIPV). The antibody response was compared with those produced by epsilon toxoid vaccines prepared using aluminium hydroxide (ALV) and incomplete Freud's adjuvant (FAV). The animals were allocated to four groups at the beginning of the trial. The animals in group 1 were vaccinated with ALV, while the animals in group 2 received FAV and those in groups 3 and 4 were vaccinated with LIPV. The animals in groups 1 to 3 received three doses of the corresponding vaccine at intervals of three weeks, while those in group 4 received only 1 dose of vaccine at the beginning of the trial. A blood sample was obtained from all the goats at the beginning of the trial and then weekly for 8 weeks. The samples were analysed for epsilon toxoid antibodies by an indirect ELISA technique. No major clinical abnormalities were observed in the animals after vaccination, with the exception of those that received the FAV, which experienced transient lameness. The highest antibody response was observed in the animals vaccinated with FAV, but they presented moderate to severe inflammatory tissue reactions at the injection site. Moderately high antibody responses were obtained with the ALV, with which only minor local reactions were observed. No significant antibody responses were obtained with the LIPV, nor were local reactions observed.

AB - A trial was performed using 20 goats to evaluate the antibody responses to a liposome-adjuvanted Clostridium perfringens epsilon toxoid vaccine (LIPV). The antibody response was compared with those produced by epsilon toxoid vaccines prepared using aluminium hydroxide (ALV) and incomplete Freud's adjuvant (FAV). The animals were allocated to four groups at the beginning of the trial. The animals in group 1 were vaccinated with ALV, while the animals in group 2 received FAV and those in groups 3 and 4 were vaccinated with LIPV. The animals in groups 1 to 3 received three doses of the corresponding vaccine at intervals of three weeks, while those in group 4 received only 1 dose of vaccine at the beginning of the trial. A blood sample was obtained from all the goats at the beginning of the trial and then weekly for 8 weeks. The samples were analysed for epsilon toxoid antibodies by an indirect ELISA technique. No major clinical abnormalities were observed in the animals after vaccination, with the exception of those that received the FAV, which experienced transient lameness. The highest antibody response was observed in the animals vaccinated with FAV, but they presented moderate to severe inflammatory tissue reactions at the injection site. Moderately high antibody responses were obtained with the ALV, with which only minor local reactions were observed. No significant antibody responses were obtained with the LIPV, nor were local reactions observed.

KW - Adjuvant

KW - Antibody

KW - Clostridium perfringens

KW - Enterotoxaemia

KW - Goats

KW - Immunity

KW - Liposomes

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=0033065535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033065535&partnerID=8YFLogxK

U2 - 10.1023/A:1006206216220

DO - 10.1023/A:1006206216220

M3 - Article

VL - 23

SP - 143

EP - 150

JO - Veterinary Research Communications

JF - Veterinary Research Communications

SN - 0165-7380

IS - 3

ER -